Objective: The aim of this study is to analyze the long-term outcomes of above-knee femoro-popliteal bypass procedures with Omniflow II biosynthetic grafts. Primary patency and graft related complications were the end points of the study.
Methods: Between January 2012 and January 2021, a total of 50 patients (42 males, 8 females) were revascularized using an in-situ Omniflow II graft. Demographic, clinical, operative and postoperative characteristics of the patients were analyzed retrospectively.
Results: Mean age was 63.8±10.1 (range 40-82) years. Fifty above-knee femoropopliteal bypass procedures were performed. Four patients (8%) were operated on due to a previous vascular graft infection where 8 (16%) were operated on due to a previous occlusion. Primary patency rate was 88%. Early graft thrombosis occurred in 2 (4%) patients where late graft stenosis unrelated to the anastomotic sites was encountered in 1 (2%) patient. An endarterectomy on either the proximal or distal site of the anastomosis were performed in 12 (24%) patients. Mean follow-up was 32.9±20.8 (range 12-90) months. Three (6%) patients died due to a COVID-19 infection. No graft infection nor mortality related to arterial bypass procedures was encountered.
Conclusion: The Omniflow II biosynthetic graft provides superior results in treatment of above-knee femoro-popliteal bypass procedures with high patency rates and low incidence of graft infection and aneurysm formation